Biomarkers of Disease Book

	List of contributors
	Preface
Pt. 1	Assessing and utilizing the diagnostic or prognostic power of biomarkers
1	Evidence-based medicine: evaluation of biomarkers	3
2	Development of biomarkers: the industrial perspective	16
3	Statistical approaches to rational biomarker selection	24
4	Using intelligent systems in clinical decision support	32
Pt. 2	Biomarkers of kidney disease and dysfunction
5	Biomarkers in renal disease	45
6	The genetics of renal disease	56
7	Early markers of nephrotoxicity for environmental and occupational monitoring	66
8	The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers	76
Pt. 3	Biomarkers of bone disease and dysfunction
9	Bone turnover markers in clinical practice	99
10	Biomarkers of bone formation	115
11	Biochemical markers of bone resorption	122
12	The clinical application of biomarkers in osteoporosis	133
13	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover	140
14	Genetic approaches to the study of complex diseases: osteoporosis	159
Pt. 4	Biomarkers of liver disease and dysfunction
15	Biomarkers of hepatic disease	167
16	The immunogenetics of metabolic liver disease	177
17	Toxicogenetic markers of liver dysfunction	190
18	Prognosis and management of patients with acute liver failure	199
19	Biomarkers in artificial and bioartificial liver support	211
20	Prognostic markers in liver disease	221
21	Apoptosis: biomarkers and the key role of mitochondria	228
22	Liver regeneration: mechanisms and markers	239
23	Determinants of responses to viruses and self in liver disease	244
24	IL-6-type cytokines and signalling in inflammation	256
Pt. 5	Biomarkers of gastrointestinal disease and dysfunction
25	Biomarkers in gastrointestinal disease	265
26	Tumour markers in gastrointestinal disease	272
27	Markers of malabsorption: coeliac disease	281
Pt. 6	Biomarkers in toxicology
28	Genomics and biomarkers in toxicology	291
29	Protein profiling and proteomic databases	299
30	Biomarkers for evaluating the safety of genetically modified foods	313
Pt. 7	Biomarkers of cardiovascular disease and dysfunction
31	The impact of biochemical tests on patient management	325
32	Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure	334
33	Serum markers of inflammation and cardiovascular risk	345
34	The clinical significance of markers of coagulation in acute coronary syndromes	355
35	Endothelin: what does it tell us about myocardial and endothelial dysfunction?	365
36	Homocysteine: a reversible risk factor for coronary heart disease	374
37	Matrix metalloproteinases and their tissue inhibitors	379
Pt. 8	Biomarkers of neurological disease and dysfunction
38	Biomarkers of neurodegenerative disorders	391
39	Traumatic brain injury: assessment by biochemical serum markers	398
40	An overview of S-100[beta] as a clinically useful biomarker of brain tissue damage	406
Pt. 9	Biomarkers in transplantation
41	Monitoring heart and lung transplant patients	415
42	Monitoring liver transplant recipients	423
43	Chronic allograft damage index as a surrogate marker for chronic allograft rejection	433
44	Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy	442
45	The use of biomarkers for monitoring the response to immunosuppressive drug therapy	451
46	Post-transplantation bone disease	461
47	Molecular diagnosis of cytomegalovirus disease	467
48	Diagnosis and monitoring of inflammatory events in transplant recipients	474
	Index	483